Wells Fargo analyst Derek Archila upgraded C4 Therapeutics (CCCC) to Overweight from Equal Weight with a price target of $12, up from $8. The shares “are cheap” and Wells is now more confident ...
Stephens initiated coverage of C4 Therapeutics (CCCC) with an Equal Weight rating and $4 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein ...
Fintel reports that on November 18, 2024, Stephens & Co. initiated coverage of C4 Therapeutics (NasdaqGS:CCCC) with a Equal-Weight recommendation. As of October 22, 2024, the average one-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback